As of 2025-12-17, the EV/EBITDA ratio of Karyopharm Therapeutics Inc (KPTI) is -3.99. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. KPTI's latest enterprise value is 333.25 mil USD. KPTI's TTM EBITDA according to its financial statements is -83.48 mil USD. Dividing these 2 quantities gives us the above KPTI EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 13.2x - 15.2x | 14.9x |
| Forward P/E multiples | 21.5x - 29.2x | 21.8x |
| Fair Price | (118.48) - (87.63) | (103.06) |
| Upside | -1971.7% - -1484.4% | -1728.1% |
| Date | EV/EBITDA |
| 2025-12-17 | -3.97 |
| 2025-12-16 | -3.99 |
| 2025-12-15 | -4.07 |
| 2025-12-12 | -4.12 |
| 2025-12-11 | -4.13 |
| 2025-12-10 | -4.02 |
| 2025-12-09 | -4.00 |
| 2025-12-08 | -3.90 |
| 2025-12-05 | -3.87 |
| 2025-12-04 | -3.91 |
| 2025-12-03 | -3.81 |
| 2025-12-02 | -3.79 |
| 2025-12-01 | -3.87 |
| 2025-11-28 | -3.85 |
| 2025-11-26 | -3.83 |
| 2025-11-25 | -3.81 |
| 2025-11-24 | -3.83 |
| 2025-11-21 | -3.90 |
| 2025-11-20 | -3.88 |
| 2025-11-19 | -3.92 |
| 2025-11-18 | -3.97 |
| 2025-11-17 | -3.88 |
| 2025-11-14 | -3.86 |
| 2025-11-13 | -3.82 |
| 2025-11-12 | -3.84 |
| 2025-11-11 | -3.81 |
| 2025-11-10 | -3.81 |
| 2025-11-07 | -3.75 |
| 2025-11-06 | -3.77 |
| 2025-11-05 | -3.79 |
| 2025-11-04 | -3.85 |
| 2025-11-03 | -3.94 |
| 2025-10-31 | -3.88 |
| 2025-10-30 | -3.92 |
| 2025-10-29 | -3.94 |
| 2025-10-28 | -3.99 |
| 2025-10-27 | -4.01 |
| 2025-10-24 | -3.99 |
| 2025-10-23 | -3.96 |
| 2025-10-22 | -3.95 |
| 2025-10-21 | -4.01 |
| 2025-10-20 | -4.02 |
| 2025-10-17 | -3.91 |
| 2025-10-16 | -3.93 |
| 2025-10-15 | -3.91 |
| 2025-10-14 | -3.88 |
| 2025-10-13 | -3.85 |
| 2025-10-10 | -3.82 |
| 2025-10-09 | -3.89 |
| 2025-10-08 | -3.90 |